Breast cancer treatment methods
Patent Information
- Application Number
- JP2023526525
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-06-01
- Filing Date
- 2021-11-05
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-11-05
AI Technical Summary
Current treatments for ER+ breast cancer, such as selective estrogen receptor modulators and aromatase inhibitors, face challenges including side effects and clinical resistance, necessitating the development of more potent ER-directed therapies that can target both wild-type and mutant ERα tumors effectively.
A selective orally available small molecule covalent estrogen receptor antagonist, Compound 1, is administered to patients based on their mutant allele frequency of ESR1 mutations, particularly focusing on clonal Y537S and D538G mutations, to predict treatment responsiveness.
Compound 1 demonstrates significant antitumor activity in ER+ breast cancer patients, particularly those with clonal Y537S or D538G mutations, extending progression-free survival and showing efficacy in heavily pretreated patients with visceral metastases.
Smart Images

Figure 2022098953000001 
Figure 2022098953000002
Abstract
Description
Technical Field
[0005] ,
[0001] Cross - reference to related applications This application claims the benefit of priority of U.S. Provisional Patent Application No. 63 / 110,787, filed on November 6, 2020; U.S. Provisional Patent Application No. 63 / 110,800, filed on November 6, 2020; U.S. Provisional Patent Application No. 63 / 117,678, filed on November 24, 2020; and U.S. Provisional Patent Application No. 63 / 195,505, filed on June 1, 2021, the contents of each of which are hereby incorporated by reference in their entirety.
[0002] Sequence Listing This application includes a sequence listing submitted electronically in ASCII format, which is hereby incorporated by reference in its entirety. The ASCII copy created on November 4, 2021 has the name 15647_0015 - 00304_SL.txt and a size of 9,309 bytes.
[0003] Embodiments relate to a method of treating breast cancer patients, particularly patients having breast cancer tumors that express estrogen receptor alpha (ERα) protein.
Background Art
[0004] Breast cancer is the most commonly diagnosed malignancy among modern women, with nearly 200,000 new cases diagnosed each year in the United States and 1.7 million new cases diagnosed worldwide. Since approximately 70% of breast tumors are positive for estrogen receptor alpha protein (ERα protein, encoded by the ESR1 gene) - a key oncogenic driver in this tumor subset - several classes of therapies that antagonize ERα function have been developed, including 1) selective estrogen receptor degrader (SERD), an example of which is fulvestrant, 2) selective estrogen receptor modulator (SERM), an example of which is tamoxifen, and 3) aromatase inhibitors that reduce systemic estrogen levels.
[0005] These therapies have generally shown effectiveness in reducing the incidence and progression of ERα+ breast tumors in clinical practice. However, these various classes of compounds are associated with on-target tendencies. For example, tamoxifen has been shown to increase the risk of endometrial cancer in clinical practice because it activates endometrial signaling activity (Fisher et al., (1994) J Natl Cancer Inst. Apr 6;86(7):527-37; van Leeuwen et al., (1994) Lancet Feb 19;343(8895):448-52). In contrast, fulvestrant is a pure antagonist and, given that ERα activity is critically important for bone formation, can lead to decreased bone density in postmenopausal women. In addition to on-target side effects, clinical resistance to these ERα antagonist classes is also emerging, highlighting the need for the development of next-generation compounds.
[0006] Several resistance mechanisms have been identified using in vitro and in vivo models of resistance to various endocrine therapies. These include increased ERα / HER2 "crosstalk" (Shou et al., (2004) J Natl Cancer Inst. Jun 16;96(12):926-35), abnormal expression of ERα coactivators / cosuppressors (Osborne et al., (2003) J Natl Cancer Inst. Mar 5;95(5):353-61), or complete loss of ERα that enables ER-independent growth (Osborne CK, Schiff R (2011) Annu Rev Med 62:233-47).
[0007] In recent years, considerable effort has been devoted to deeply genetically characterizing endocrine therapy-resistant metastases isolated from patients, with the hope of identifying clinically relevant resistance mechanisms. Recently, several independent laboratories have published numerous genetic lesions observed in resistant tumors compared to primary tumors (Li et al., (2013) Cell Rep. Sep 26;4(6):1116-30; Robinson et al., (2013) Nat Genet. Dec;45(12):1446-51; Toy et al., (2013) Nat Genet. 2013 Dec;45(12):1439-45). Among these, there are highly repetitive mutations in the ligand-binding domain of ESR1 (the gene encoding the ERα protein), and it has been found that these are significantly enriched in about 20% of resistant tumors compared to tumors not treated with endocrine therapy (Jeselsohn et al.,(2014) Clin Cancer Res. Apr 1;20(7):1757-67;Toy et al.,(2013) Nat Genet. 2013 Dec;45(12):1439-45;Robinson et al.,(2013) Nat Genet. Dec;45(12):1446-51;Merenbakh-Lamin et al.,(2013) Cancer Res. Dec 1;73(23):6856-64;Yu et al.,(2014) Science Jul 11;345(6193):216-20;Segal and Dowsett (2014), Clin Cancer Res Apr 1;20(7):1724-6) suggests that these mutations may functionally drive clinical resistance. In contrast to the enrichment of ESR1 mutations observed in treatment-resistant tumors, mutations in other cancer-related genes did not reveal such robust enrichment, strongly implying the importance of ERα mutations in promoting resistance (Jeselsohn et al., (2014) Clin Cancer Res. Apr 1;20(7):1757-67).
[0008] The average ER+ breast cancer patient is treated with seven independent therapies, including chemotherapy and various anti-estrogen therapies such as tamoxifen, fulvestrant, and aromatase inhibitors. Recent genomic profiling has revealed that, with the emergence of activating mutations in ERα, the ERα pathway remains a critically important driver of tumor growth in the resistance setting. Therefore, it is critically important to develop more potent ER-targeted therapies that can overcome resistance in the clinical setting. Thus, there is a need for novel compounds that can potently suppress the growth of both wild-type (WT) tumors and ERα mutant-positive tumors, and for methods to better target these compounds to patients who are expected to respond to therapy.
[0009] One compound reported to be useful in the treatment of ER+ breast cancer patients is (E)-N,N-dimethyl-4-((2-((5-((Z)-4,4,4-trifluoro-1-(3-fluoro-1H-indazole-5-yl)-2-phenylbuta-1-en-1-yl)pyridine-2-yl)oxy)ethyl)amino)buta-2-enamide, shown below as Compound 1: [ka]
[0010] Compound 1 is a selective, orally administered small molecule covalent estrogen receptor (ERα) antagonist. Compound 1 is further reported in U.S. Patent No. 9,796,683 B2, "Tetrasubstituted Alkene Compounds and Their Use" (which is incorporated herein by reference in its entirety as completely rewritten). Compound 1 has been reported to covalently bind to the cysteine residue at position 530 of ERα proteins in both wild-type and constitutively active mutants, including Y537S. Compound 1 has demonstrated significant antitumor activity in several PDX breast cancer models, including those with mutations in ESR1 (the gene encoding ERα). A pharmaceutically acceptable salt of this compound has also been reported to be useful in the treatment of ER+ breast cancer patients. For example, Compound 1 may be used as a hydrochloride salt, which may be in crystalline form, as described in U.S. Patent No. 10,640,483 B2 (which is incorporated herein by reference in its entirety as completely rewritten). Compound 1 is formulated as a capsule or tablet, as described in patent application PCT / US2020 / 033292, filed on 15 May 2020 and incorporated herein by reference in its entirety as completely rewritten. [Overview of the Initiative] [Problems that the invention aims to solve]
[0011] Compound 1 has been shown to be useful in treating ER+ breast cancer patients, but it would be useful to be able to better predict which cancer patients will show a higher response and therefore are more likely to benefit from the treatment. One aspect of this disclosure relates to a method of better predicting the likelihood of a patient showing a favorable response to treatment with Compound 1 or a pharmaceutically acceptable salt thereof, using the mutant allele frequency of the patient. [Means for solving the problem]
[0012] Various embodiments disclosed herein provide methods for treating cancer, particularly breast cancer, in patients in need, for example, a method comprising administering compound 1 or a pharmaceutically acceptable salt thereof to a patient having, for example, a first mutant allele frequency value of 0.5% or more of a first ESR1 mutant in cfDNA in a blood sample. In some embodiments, the patient is further administered one or more cancer treatments, for example, one or more breast cancer treatments.
[0013] In some embodiments, the first ESR1 mutant is located at Y537. In some embodiments, the first ESR1 mutant is Y537S. In some embodiments, the patient has a second mutant allele frequency value of the second ESR1 mutant, and the second mutant allele frequency value is less than 0.5%. In some embodiments, the second ESR1 mutant is located at D538. In some embodiments, the second ESR1 mutant is D538G. In some embodiments, the second ESR1 mutant is L536H, L536P, L536Q, L536R, Y537C, Y537N, D538G, or E380Q.
[0014] In some embodiments, the first ESR1 mutant is located at D538. In some embodiments, the first ESR1 mutant is D538G. In some embodiments, the patient has a second mutant allele frequency value of the second ESR1 mutant, and the second mutant allele frequency value is less than 0.5%. In some embodiments, the second ESR1 mutant is located at Y537. In some embodiments, the second ESR1 mutant is Y537S. In some embodiments, the second ESR1 mutant is L536H, L536P, L536Q, L536R, Y537C, Y537N, Y537S, or E380Q.
[0015] In some embodiments, the frequency of the first mutant allele is greater than 0.6%. In some embodiments, the frequency of the first mutant allele is greater than 0.7%. In some embodiments, the frequency of the first mutant allele is greater than 0.8%. In some embodiments, the frequency of the first mutant allele is greater than 0.9%. In some embodiments, the frequency of the first mutant allele is greater than 1.0%.
[0016] In some embodiments, the frequency of the second mutant allele is less than 0.4%. In some embodiments, the frequency of the second mutant allele is less than 0.3%. In some embodiments, the frequency of the second mutant allele is less than 0.2%. In some embodiments, the frequency of the second mutant allele is less than 0.1%.
[0017] In some embodiments, ERα mutations are measured directly from tumor samples. In such embodiments, samples from patients selected for treatment may indicate the presence of D537 mutations or D538 mutations.
[0018] In some embodiments, the patient exhibits a PgR-positive state. [Brief explanation of the drawing]
[0019] [Figure 1] As discussed in Examples 1 and 2, treatment with compound 1 shows that patients with clonal D538G or clonal Y537S ESR1 mutations have a longer progression-free survival (PFS). [Figure 2] The combined PFS results of patients with clonal D538G and clonal Y537S ESR1 mutations are shown in comparison to those of other patients. [Figure 3]As reported in Example 3, it shows that the efficacy may be higher in patients with PgR+ tumors. The text in the inset is read as follows: PgR positive (≥1% positive cells), N = 38, 24 events, median (95%) = 5.4 (2.0, 8.8) months. PgR negative (≤1% positive cells), N = 34, 20 events, median (95%) = 2.1 (1.7, 7.4) months. [Figure 4] Shows progression-free survival based on the ESR1 mutation status as reported in Example 3. The text in the inset is read as follows: Clonal Y537S, N = 10, 8 events, median (95%Cl) = 7.3 (0.8, 11.2) months. Clonal D538G, N = 19, 13 events, median (95%Cl) = 5.4 (1.7, 7.2) months. Polyclonal Y537S and D538G, N = 4, 3 events, median (95%Cl) = 3.5 (1.7, 5.4) months. Y537S and D538G negative, N = 61, 33 events, median (95%Cl) = 3.8 (2.0, 7.3) months. [Figure 5] Shows the relationship between the detection of ESR1 mutations in the blood and the PgR expression level in the tumor.
BEST MODE FOR CARRYING OUT THE INVENTION
[0020] Unless otherwise defined, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the subject matter disclosed herein belongs. In the practice or testing of the subject matter disclosed herein, any methods, apparatus, and materials similar or equivalent to those described herein can be used, but representative methods, apparatus, and materials are described herein.
[0021] Unless otherwise specified, or in the context where combinations are mentioned and it is not clearly implied to the contrary, any combination of the methods or process steps as used herein can be carried out in any order.
[0022] The methods and apparatuses of the present disclosure can include, consist of, or consist essentially of the essential elements and limitations of the embodiments described herein, including their components, as well as any additional or optional components or limitations described herein or any other useful ones.
[0023] Unless otherwise indicated, all numerical values representing characteristics such as physical dimensions, component amounts, reaction conditions, etc. used in this specification and the claims are to be understood as being modified by the term "about" in all instances. Thus, unless otherwise indicated to the contrary, the numerical parameters set forth in this specification and the claims are approximations that can vary depending upon the desired characteristics to be achieved by the subject matter disclosed herein.
[0024] The following definitions may be useful for understanding the embodiments as presented herein.
[0025] As used herein, the term "sample" refers to a material or mixture of materials containing one or more target components. A sample from a subject refers to a sample obtained from the subject, including samples of biological tissue or fluid origin obtained, accessed, or collected in vivo or in situ. Samples can be obtained from an area of a subject having pre-cancerous or cancerous cells or tissue, or from another tissue or fluid of the subject. Such samples can be, but are not limited to, organs, tissues, fractions, and cells removed from a mammal. Exemplary samples include lymph nodes, whole blood, partially purified blood, serum, plasma, bone marrow, and peripheral blood mononuclear cells ("PBMCs"). A sample can also be a tissue biopsy. Exemplary samples also include cell lysates, cell cultures, cell lines, tissues, oral tissues, gastrointestinal tissues, organs, organelles, biological fluids, blood samples, urine samples, skin samples, and the like.
[0026] As used herein, the term "subject" refers to a mammal. The subject can be a human or non-human mammal, such as a dog, cat, cow, horse, mouse, rat, rabbit, or transgenic species thereof. In some embodiments, the subject is a human.
[0027] cfDNA: As used herein, “cfDNA” refers to cell-free DNA in the blood circulation of the subject, and may include DNA from blood cells, viruses, parenchymal organs, and many other sources. Xia L. et al. reported that in healthy individuals, more than 90% of cfDNA comes from blood cell debris (Xia, L. et al., “Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals”, Scientific Reports 7:7526; DOI:10.1038 / s41598-017-06106-1).
[0028] As used herein, "ctDNA" refers to circulating tumor DNA in the plasma of cancer patients. Xia L. et al. reported that in cancer patients, tumor-associated ctDNA accounts for 0.1–0.01% of plasma cfDNA.
[0029] As used herein, “wild-type” or “WT” refers to the dominant type in which a nucleotide or amino acid sequence exists. The dominant type can be identified in a sample from a subject and / or determined based on the dominant type of nucleotide or amino acid sequence observed in a subject population, such as the human population. For example, if 80% of the nucleotide sequences in a human population contain an adenosine base at a particular location, and the remaining sequences contain cytosine, thymine, or guanine at that location, the wild-type is said to have adenosine at that location. Similarly, if 80% of the protein sequences in a human population contain a glycine residue at a particular location, and the remaining sequences contain some other amino acid residue, glycine is said to be the wild-type residue.
[0030] A subject or sample from a subject may have multiple copies of the ESR1 gene. These copies may encode wild-type and / or mutant ERα proteins. When used herein, a subject or sample from a subject with an ESR1 mutation may also have one or more copies of the wild-type ESR1 gene and / or wild-type ERα protein.
[0031] As used herein, “mutant allele frequency” or “MAF” is a fractional value obtained by dividing the number of individual gene reads carrying a particular mutation at a given location compared to the wild-type sequence by the total number of individual gene reads contained within the same locus. For example, if the total sequencing depth for a given sequence location is 10,000 and adenine (A) bases account for 9,900 individual occurrences, the remaining individual occurrences in the sequencing may include, for example, 23 occurrences with thymine (T) bases at the same location, 42 occurrences with cytosine (C) bases at the same location, and 35 occurrences with guanine (G) bases at the same location. Since the vast majority of sequences have an adenine base at that location (and therefore donate adenine as the “wild-type” base at that location), the mutant allele frequency with a thymine (T) base is calculated as (T) / (T+C+G+A), i.e., 23 / 10000 = 0.0023. Those skilled in the art understand that genetic codes are redundant, and therefore, mutant allele frequencies can also be calculated based on codons that code for specific amino acids in a particular protein sequence. Thus, MAF values reflecting amino acid mutations can group together all nucleic acid sequences that code for the same mutation. Those skilled in the art also recognize that a single gene can code for amino acid mutations located at different locations. Therefore, MAF values may be calculated for multiple amino acid mutations located at different locations within a single gene.
[0032] As used herein, “mutant ERα protein” refers to a non-wild-type ERα protein having at least one amino acid mutation compared to the wild type (this protein may also be referred to as mutant “ESR1”). As used herein, “ESR1 mutant” refers to at least one mutation in the ESR1 gene encoding the ERα protein. “ERα MAF” or “ESR1 MAF” refers to the frequency of ESR1 mutants encoding mutant ERα protein. In some embodiments, the wild-type ESR1 gene is Sequence ID No. 2. In some embodiments, the amino acid sequence of the wild-type ERα protein is Sequence ID No. 1.
[0033] As used herein, “constitutively active mutant” refers to a non-wild-type protein that is active without requiring a bound ligand, such as an ERα protein that is active even in the absence of estrogen.
[0034] Those skilled in the art will recognize that various methods and techniques, including techniques known in the art such as next-generation sequencing (NGS) and droplet digital PCR (ddPCR), can be used in MAF assays. For example, one useful tool is the Sysmex® Inostics Liquid Biopsy (ONCOBEAM®) ctDNA biomarker standard test (www.sysmex-inostics.com; see https: / / cdn2.hubspot.net / hubfs / 5871980 / OncoBEAM_ctDNA_Testing_in_Clinical_Practice_NSCLC_web.pdf). For further description and use of this assay, see Oxnard, G et al. J. Clin. Oncol. 34(28):3375-3382 (2016); Wu, Y et al. MA08.03 J. Thorac. Oncol. 12, S386 (2017); Mok, T et al. N. Engl. J. Med. 376, 629-640 (2017); and Thress K et al. Poster presented at: European Society for Medical Oncology (See 2014 Congress; 2014 Sep 26-30; Madrid, Spain; #1270P; 25. Murtaza M. et al. Nature. 497, 108-112 (2013)). This diagnostic test can detect any ESR1 mutation and its corresponding MAF with a low sensitivity limit of 0.05%.
[0035] Those skilled in the art will recognize that different ESR1 mutations can result in ERα proteins with a variety of mutations, including one or more of the following amino acid sequence mutations: E380Q, L536H, L536P, L536Q, L536R, Y537S, Y537C, Y537N, D538G, or other mutations. In some embodiments, the MAF for mutations at specific positions in the ERα protein sequence, particularly the mutations at amino acid positions 537 and / or 538 of SEQ ID NO: 1 (in contrast to ESR1 gene mutations at codons at positions where the nucleic acid sequence is modified but still encodes a wild-type amino acid residue at a given position in the ERα protein), is evaluated by the method disclosed herein.
[0036] As used herein, a patient is said to have a “clonal” ERα mutation when ctDNA diagnosis reveals that a specific ESR1 MAF (encoding a specific ERα mutation) value is, for example, 0.5% or higher in a blood sample, but all other ESR1 MAF values (encoding any other ERα mutation) are less than 0.5%. For example, if a patient encoding a Y537S mutation has a ctDNA with a MAF value of 0.5% or higher, but all other ERα MAF values (including, but not limited to, D538G, L536H, L536P, L536Q, L536R, Y537C, Y537N, and E380Q MAF) are less than 0.5%, then that patient has a clonal Y537S ERα mutation. In another example, if a patient's ctDNA encoding the D538G mutation is found to be 0.5% or greater, while all other ERα MAF values (but not limited to, Y537S, L536H, L536P, L536Q, L536R, Y537C, Y537N, and E380Q MAF) are each found to be less than 0.5%, then that patient has a clonal D538G ERα mutation.
[0037] In contrast, a patient is said to have a "polyclonal" ERα mutation when ctDNA diagnosis reveals that two or more specific ERα MAF (multiple ERα mutations) values are each 0.5% or higher. For example, if a patient's ctDNA contains 0.5% or higher MAFs encoding both the Y537S mutation and the D538G mutation, that patient has a polyclonal ERα mutation.
[0038] In one embodiment of the present invention, patients with a clonal Y537S ERα mutation may preferentially benefit from treatment with compound 1 and a pharmaceutically acceptable salt thereof. In another embodiment of the present invention, patients with a clonal D538G ERα mutation may preferentially benefit from treatment with compound 1 and a pharmaceutically acceptable salt thereof.
[0039] Those skilled in the art will recognize that, in order to select patients most likely to respond to treatment with compound 1, the patient's progesterone receptor (PgR) status may also be measured in combination with, for example, ERα MAF. The PgR status may be detected by immunohistochemistry and / or sequencing. In some embodiments of this disclosure, patients who would benefit from treatment with compound 1 are PgR-positive in addition to having a clonal Y537S mutation or a clonal D538G mutation.
[0040] As used herein, "QTcF" is the electrocardiogram QT interval corrected for heart rate using the Fridericia formula.
[0041] As used herein, "MTD" refers to the maximum tolerance.
[0042] When used herein, RP2D is the recommended dose for Phase 2.
[0043] Those skilled in the art will readily see that other suitable modifications and adaptations of the method described herein can be made using suitable equivalents. While the method has been described in detail here, this will be more clearly understood by referring to the following examples, which are included for illustrative purposes only and are not intended to be limiting. [Examples]
[0044] Example 1A - Overview Compound 1 was tested in a first-in-human phase 1 / 2 study in women with locally advanced or metastatic ER+, HER2-negative breast cancer. In this multicenter study, women with locally advanced or metastatic ER+, HER2- breast cancer were treated with Compound 1 administered in 28-day cycles with QD and PO after progression following at least one course of hormone therapy and at least one course of additional therapy / regimen.
[0045] The primary objective of Phase 1 was to determine the monthly treatment duration (MTD) and rate of progression-free survival (RP2D) in patients with previously treated ER-+, HER2- metastatic breast cancer. Secondary objectives included safety and antitumor activity. The primary objective of Phase 2 was to estimate the efficacy of the drug in terms of objective response rate (ORR), clinical benefit rate (CBR), and progression-free survival (PFS). Secondary objectives included safety. This study was designed to exclude patients with a 5% ORR lower limit at a one-sided significance level of 0.05 and 90% power.
[0046] Example 1B - Demographic Information and Patient Characteristics Over a 30-month period, 130 patients were enrolled; 47 in the Phase 1 part of the study and 83 in the Phase 2 part. A total of 105 patients, including 73 who received 450 mg, were evaluable for response. As shown in Table 1, the median age was 62 years (range: 31–87 years), and 82% had liver and / or lung metastases.
[0047] [Table 1]
[0048] The median number of prior treatments for metastatic disease was 3 (range: 1-10), and 41% of patients had received four or more prior treatments in a metastatic setting (Table 2). 87%, 71%, and 54% of patients had a history of CDK4 / 6 inhibitors, fulvestrant, and chemotherapy, respectively. Using a circulating plasma DNA assay (Sysmex Inostics® Liquid Biopsy OncoBEAM® ctDNA biomarker standard test; mutation detection limit: 0.05% mutant allele frequency), 75 patients (58%) had detectable ESR1 mutations.
[0049] [Table 2]
[0050] Example 1C - Safety In the Phase 1 part, once-daily doses of 100–600 mg were evaluated. No dose-limiting toxicities (DLTs) were observed up to a dose of 450 mg, and in the 600 mg cohort, two DLTs (grade 3 fatigue and grade 3 drug eruption) were observed in two out of seven subjects. Consequently, the 450 mg dose was selected as the RP2D.
[0051] Grade 2 or higher adverse events reported in more than 10% of the subjects were anemia (20%), fatigue (16%), nausea (14%), diarrhea (11%), and elevated AST (11%). Three cases of grade 4 AEs (serum bilirubin, urinary tract obstruction, and hyponatremia) were reported, all considered to be related to disease progression. Grade 1 sinus bradycardia (asymptomatic) was reported in 35%, and grade 2 (symptomatic, no intervention required) was reported in 4%. Grade 2 and 3 QTcF prolongation were reported in two and three subjects, respectively. There were no treatment-related deaths.
[0052] Example 1D - Effectiveness In the evaluable response group, 13 confirmed partial responses (PR, 12%, 90% confidence interval: 7.5%–19%) were observed, including 11 PRs (15%, 90% confidence interval: 8.7%–23.7%) at the 450 mg dose, thus achieving the primary objective of this study (Table 3). Disease stability (SD) and clinical benefit rates (≥23 weeks) were 45% and 33% at the 450 mg dose, respectively, and 46% and 34% at the total dose. Responses were observed in patients with multiple prior treatment histories, patients with visceral metastases, and patients with prior treatment of fulvestrant, CDK4 / 6 inhibitors, and / or chemotherapy in a metastatic setting.
[0053] [Table 3]
[0054] Using Kaplan-Meier analysis, the median PFS among subjects who started with a 450 mg dose was determined to be 3.8 months (95% CI: 3.2–6.2).
[0055] Example 2 - Discovery of the effects of clonal Y537S and clonal D538G ESR1 mutations The experiments conducted following the one reported in Example 1 concerned the identification of parameters driving the activity of compound 1 in the test population. Two parameters were of particular interest: 1) PgR status, and 2) ESR1 mutant type and allele frequency. Since PFS is a continuous variable, PFS was used for these analyses. Because it is known that the ER receptor induces PgR expression (PgR+ indicates the presence of ER activity and therefore a higher potential effect of ER inhibitors), pretreatment PgR positivity was expected to be associated with a longer PFS in the compound 1 treatment population. The effect of baseline circulating ESR1 of specific ESR1 mutants and their allele frequencies were unknown.
[0056] Potential biomarker / treatment interactions were explored using receiver operating characteristics (ROC) analysis. The effect of detecting ESR1 mutations in the pretreatment blood, independent of the presence of other ESR1 mutations, was examined. The Y537S ESR1 mutation appeared to predict a better outcome than median PFS (3.8 months), with an area under the ROC curve of 0.857 (p=0.007). The optimal criterion was a MAF of over 0.34% of serum Y537S ESR1 with 100% sensitivity and 50% specificity to observe PFS greater than 3.8 months. A trend (AUC=738, p=0.13) was also observed when both ESR1 mutations, Y537S and / or D538G, were considered together. No significant effect was observed with other mutations in this ROC analysis.
[0057] Next, the effect of pretreatment detection of PgR positivity and ESR1 mutations Y537S and D538G on median PFS was investigated using the Kaplan-Meier method. The effect of ESR1 clonality was also examined, as the simultaneous presence of multiple ESR1 mutation clones likely indicates a highly advanced or complex disease. Notably, the allele frequencies of different ESR1 mutants were not identical, suggesting that multiple clones exist within a single tumor rather than multiple mutations existing in the same tumor ESR1 gene. For the purposes of these analyses, clonal Y537S was defined as an ESR1 Y537S mutation detected with a mutant allele frequency (MAF) of 0.5% or higher in pretreatment whole blood samples, while the MAF of D538G was less than 0.5%. Conversely, clonal D538G was defined as an ESR1 D538G mutation detected with an MAF of 0.5% or higher in pretreatment whole blood samples, while the MAF of Y537S was less than 0.5%.
[0058] These analyses showed that the median PFS was 3.8 months (95% CI: 3.2–6.2) among subjects starting at a 450 mg dose, and 5.5 months in subjects with clonal ESR1 Y537S or clonal D538G mutations. Considering both PgR positivity and the presence or absence of clonal ESR1 Y537S or clonal D538G mutations, PFS for subpopulations of the subjects is shown in Table 4 and Figure 5. Using the ROC method, the subject allocation criteria were established as shown in Table 4 and Figure 5. After testing each ESR1 mutant individually, according to the ROC analysis, this trial truly predicted a favorable outcome for that patient only when Y537S had an MAF value of 0.5% or higher (and other mutants had an MAF value below 0.5%), or when D538G had an MAF value of 0.5% or higher (and other mutants had an MAF value below 0.5%). The highest clinical benefit was observed in patients whose tumors were PgR-positive and carried either a clonal ESR1 Y537S or clonal D538G mutation. The lowest median progression-free survival (PFS) was observed in patients who simultaneously carried both ESR1 Y537S and D538G mutations.
[0059] [Table 4]
[0060] Figure 1 shows that clonal D538G or clonal Y537S ESR1 mutations are associated with the activity of compound 1, as discussed above. Figure 2 shows the overall outcomes for patients with clonal D538G or clonal Y537S ESR1 mutations. In both figures, progression-free survival is graphed as the progression-free rate against time from randomization of the patient population. These results demonstrate a remarkable response to treatment outcomes with compound 1 in these patient groups compared to patients treated with fulvestrant, which can be considered standard treatment. Fribbens, C. et al., J. Clin. Onc., 34(25):2961-2968. These same mutations, whether clonal or polyclonal, are not positive prognostic factors for treatment with fulvestrant. Ibid.
[0061] Example 3A - Summary - Further Clinical Data Analysis Following the data analysis described above, the patients remained in the Phase 2 study reported in Example 1, and clinical data collection continued. The primary objective of this study was to estimate the efficacy of compound 1 in terms of best overall response rate (ORR), duration of response (DoR), clinical benefit rate, and progression-free survival (PFS) in all subjects, as well as in subjects with and without ERα mutations (ERαMUT).
[0062] Example 3B - Demographic Information and Patient Characteristics In the Phase 2 study of Example 1, 83 patients were treated with 450 mg. In addition, 11 patients treated with 450 mg in the Phase 1 part of this study (also discussed in Example 1) were combined with these 83 Phase 2 patients and discussed in this example. This brought the total number of patients treated with 450 mg to 94. The patients had a wide range of prior treatment histories, and 85% of the patients had a history of receiving CDK4 / 6 inhibitors.
[0063] [Table 5]
[0064] Example 3C - Effectiveness Responses were observed in patients with multiple prior treatment histories, patients with visceral metastases, and patients with prior treatment of fulvestrant, CDK4 / 6 inhibitors, and / or chemotherapy in a metastatic setting (see Table 6).
[0065] [Table 6]
[0066] In 10 patients where clonal ESR1 Y537S was the primary ERα driver, partial response was observed in 3 cases (30%) and disease stabilization in 4 cases (40%) (see Table 7).
[0067] The median progression-free survival for all 94 patients and for the 10 patients with clonal ESR1 Y537S was 5.1 months and 7.3 months, respectively.
[0068] Potentially higher activity was observed in progesterone receptor-positive (PgR+) patients and patients with ESR1 Y537S (see Figures 3 and 4 and Table 7).
[0069] [Table 7]
[0070] Example 3D - Conclusion Based on the data analysis results of Example 3, the inventors concluded that monotherapy with 450 mg of compound 1 once daily (i.e., compound 1 monotherapy) demonstrated antitumor activity in ER+, HER2-, metastatic breast cancer patients with multiple prior treatment histories. Confirmed responses were observed in patients with visceral disease, ESR1 mutations, and prior treatment with fulvestrant, CDK4 / 6 inhibitors, and chemotherapy. The data suggest potentially high activity of compound 1 in patients with ESR1 Y537S clonal mutations and in patients with PgR+ tumors.
[0071] Array of selections: ERα amino acid sequence (SEQ ID NO: 1) [ka]
[0072] ESR1 wild-type sequence (sequence number 2) [ka] [ka] [ka]
Claims
1. Compound 1: 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof for use in treating a cancer patient having a first mutant allele frequency ("MAF") value of a first ERα mutant of 0.5% or greater.
2. The pharmaceutical composition of claim 1 , wherein the first ERα mutation is Y537S.
3. 3. The pharmaceutical composition of claim 1 or 2, wherein the patient has a second MAF value for a second ERα mutant, the second MAF value being less than 0.5%.
4. The method of claim 3, wherein the second ERα mutation is D538G.
5. 4. The pharmaceutical composition of claim 3, wherein the second ERα mutation is L536H, L536P, L536Q, L536R, Y537C, Y537N, or E380Q.
6. The method of claim 1 , wherein the first ERα mutation is D538G.
7. 7. The pharmaceutical composition of claim 6, wherein the patient has a second MAF value for a second ERα mutant, the second mutant allele frequency value being less than 0.5%.
8. The method of claim 7, wherein the second ERα mutation is Y537S.
9. 8. The pharmaceutical composition of claim 7, wherein the second ERα mutation is L536H, L536P, L536Q, L536R, Y537C, Y537N, or E380Q.
10. The pharmaceutical composition of any one of claims 1 to 9, wherein the first MAF value is greater than 0.6%.
11. 11. The pharmaceutical composition of claim 10, wherein the first MAF value is greater than 0.7%, greater than 0.8%, greater than 0.9%, or greater than 1.0%.
12. 10. The pharmaceutical composition of any one of claims 3 to 5 or 7 to 9, wherein the second MAF value is less than 0.4%.
13. 13. The pharmaceutical composition of claim 12, wherein the second MAF value is less than 0.3%, less than 0.2%, or less than 0.1%.
14. The pharmaceutical composition according to any one of claims 1 to 13, wherein the patient exhibits a PgR positive status.
15. A pharmaceutical composition described in any one of claims 1 to 14, wherein the first MAF is measured in a blood sample from the patient.
16. A pharmaceutical composition described in any one of claims 1 to 14, wherein the first MAF is measured in cfDNA from a blood sample from the patient.
17. The pharmaceutical composition described in any one of claims 1 to 16, wherein the cancer is breast cancer.
18. The pharmaceutical composition described in claim 17, wherein the breast cancer is metastatic breast cancer.
19. The pharmaceutical composition described in claim 17 or 18, wherein the breast cancer is HER2-negative breast cancer.
20. The pharmaceutical composition described in any one of claims 1 to 19, wherein the patient has received at least one treatment selected from fulvestrant, a CDK4 / 6 inhibitor, and chemotherapy.
21. Compound 1: 【Chemistry 2】 or a pharma- ceutical acceptable salt thereof, comprising the steps of: determining a first mutant allele frequency (MAF) value for a first ERa mutant and a second MAF value for a second ERa mutant, said first and second MAF values being measured in a sample from the patient; identifying the patient as suitable for treatment with Compound 1, or a pharma- ceutically acceptable salt thereof, if the first MAF value is greater than or equal to 0.5% and the second MAF value is less than 0.5%. The method includes:
22. The method described in claim 21, wherein the first ERα mutant is Y537S and the second ERα mutant is D538G.
23. The method described in claim 22, wherein the cancer is breast cancer.
